Skip to main content

Ponatinib/Chemotherapy Granted Accelerated Approval for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

The FDA has granted accelerated approval to ponatinib (Iclusig®, Takeda Pharmaceuticals USA, Inc.) with chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).   Why it matters: "Tyrosine kinase inhibitors (TKIs) are a critical component in the treatment of newly diagnosed Ph+ ALL; their use has dramatically improved outcomes among patients with this condition," said Dr. Tristan Knight, MD, FRCPC, an Oncology Data Ad...

Continue reading